Brief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
May 5 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST: EGETIS ANNOUNCES GRANT OF PATENT FOR MCT8 DEFICIENCY COMPOSITION IN U.S. Source text: ID:nMFN2yg4fv Further company coverage: EGTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Egetis Therapeutics AB (publ)
See all newsBrief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1